ArticleMolecular cancer therapeutics2014

Pharmacologic suppression of JAK1/2 by JAK1/2 inhibitor AZD1480 potently inhibits IL-6-induced experimental prostate cancer metastases formation.

Lei Gu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.